Satavaptan

Satavaptan (INN; developmental code name SR121463, former tentative brand name Aquilda) is a vasopressin-2 receptor antagonist[1] which was investigation by Sanofi-Aventis and was under development for the treatment of hyponatremia. It was also being studied for the treatment of ascites.[2] Development was discontinued in 2009.[3] References .mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output... [wikipedia]